The stock reached $42.04 before the opening bell as the market processed data from the 52-week study. Rezpegaldesleukin is designed to treat moderate-to-severe atopic dermatitis, a condition where an overactive immune system and a compromised skin barrier lead to chronic inflammation and itching. Unlike traditional therapies, this regulatory T-cell biologic aims to address the underlying immune imbalance.

Clinical Durability and Dosing

According to the company report, the 36-week blinded maintenance period highlighted the drug's long-term efficacy across varied dosing intervals. The study found that a significant portion of the patient cohort maintained their level of improvement:

• Between 71% and 83% of patients sustained their clinical response.
• 85% of patients on monthly doses achieved clear or almost clear skin.
• 63% of patients on quarterly doses met the same clearance threshold.

The findings suggest that rezpegaldesleukin may offer a durable treatment option for a patient population often requiring frequent interventions. By stabilizing the immune response, Nektar aims to provide a more consistent management strategy for those suffering from the most severe forms of the disease.